These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36777974)

  • 21. Evidence base for using atypical antipsychotics for psychosis in adolescents.
    Datta SS; Kumar A; Wright SD; Furtado VA; Russell PS
    Schizophr Bull; 2014 Mar; 40(2):252-4. PubMed ID: 24361758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Achieving the Lowest Effective Antipsychotic Dose for Patients with Remitted Psychosis: A Proposed Guided Dose-Reduction Algorithm.
    Liu CC; Takeuchi H
    CNS Drugs; 2020 Feb; 34(2):117-126. PubMed ID: 31741178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Switching antipsychotic medication to reduce sexual dysfunction in people with psychosis: the REMEDY RCT.
    Crawford MJ; Thana L; Evans R; Carne A; O'Connell L; Claringbold A; Saravanamuthu A; Case R; Munjiza J; Jayacodi S; Reilly JG; Hughes E; Hoare Z; Barrett B; Leeson VC; Paton C; Keown P; Pappa S; Green C; Barnes TR
    Health Technol Assess; 2020 Sep; 24(44):1-54. PubMed ID: 32930090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study.
    Morrison AP; Pyle M; Maughan D; Johns L; Freeman D; Broome MR; Husain N; Fowler D; Hudson J; MacLennan G; Norrie J; Shiers D; Hollis C; James A;
    Lancet Psychiatry; 2020 Sep; 7(9):788-800. PubMed ID: 32649925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and demographic predictors of continuing remission or relapse following discontinuation of antipsychotic medication after a first episode of psychosis. A systematic review.
    Bowtell M; Ratheesh A; McGorry P; Killackey E; O'Donoghue B
    Schizophr Res; 2018 Jul; 197():9-18. PubMed ID: 29146020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mental Health Staff's Perspectives on Tapering of Antipsychotic Medication: A Focus Group Study.
    Roed K; Buus N; Nielsen J; Christensen PS; Midtgaard J
    Qual Health Res; 2023 Nov; 33(13):1165-1176. PubMed ID: 37710394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beyond Clinical Remission in First Episode Psychosis: Thoughts on Antipsychotic Maintenance vs. Guided Discontinuation in the Functional Recovery Era.
    Alvarez-Jimenez M; O'Donoghue B; Thompson A; Gleeson JF; Bendall S; Gonzalez-Blanch C; Killackey E; Wunderink L; McGorry PD
    CNS Drugs; 2016 May; 30(5):357-68. PubMed ID: 27106296
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a systematic review and meta-analysis of randomised controlled trials.
    Højlund M; Kemp AF; Haddad PM; Neill JC; Correll CU
    Lancet Psychiatry; 2021 Jun; 8(6):471-486. PubMed ID: 34023019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How long should antipsychotic treatment be continued after a single episode of schizophrenia?
    Emsley R; Kilian S; Phahladira L
    Curr Opin Psychiatry; 2016 May; 29(3):224-9. PubMed ID: 26967313
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Definitions of relapse in trials comparing antipsychotic maintenance with discontinuation or reduction for schizophrenia spectrum disorders: A systematic review.
    Moncrieff J; Crellin NE; Long MA; Cooper RE; Stockmann T
    Schizophr Res; 2020 Nov; 225():47-54. PubMed ID: 31604607
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aripiprazole in the treatment of schizophrenia: a consensus report produced by schizophrenia experts in Italy.
    Cassano GB; Fagiolini A; Lattanzi L; Monteleone P; Niolu C; Sacchetti E; Siracusano A; Vita A
    Clin Drug Investig; 2007; 27(1):1-13. PubMed ID: 17177576
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment.
    Viguera AC; Baldessarini RJ; Hegarty JD; van Kammen DP; Tohen M
    Arch Gen Psychiatry; 1997 Jan; 54(1):49-55. PubMed ID: 9006400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dosing and switching of paliperidone ER in patients with schizophrenia: recommendations for clinical practice.
    Peuskens J; Rubio G; Schreiner A
    Ann Gen Psychiatry; 2014 Apr; 13(1):10. PubMed ID: 24690136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of cannabis use and its cessation on the dosage and the efficacy of antipsychotic drugs in in- and outpatients with schizophrenia taking medication: A systematic review and meta-analysis.
    Rault O; Romeo B; Butlen-Ducuing F; Rari E; Benyamina A; Martelli C
    J Psychiatr Res; 2022 Dec; 156():713-721. PubMed ID: 36410310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psychosocial interventions for people with schizophrenia or psychosis on minimal or no antipsychotic medication: A systematic review.
    Cooper RE; Laxhman N; Crellin N; Moncrieff J; Priebe S
    Schizophr Res; 2020 Nov; 225():15-30. PubMed ID: 31126806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomised controlled trial of gradual antipsychotic reduction and discontinuation in people with schizophrenia and related disorders: the RADAR trial (Research into Antipsychotic Discontinuation and Reduction).
    Moncrieff J; Lewis G; Freemantle N; Johnson S; Barnes TRE; Morant N; Pinfold V; Hunter R; Kent LJ; Smith R; Darton K; Horne R; Crellin NE; Cooper RE; Marston L; Priebe S
    BMJ Open; 2019 Nov; 9(11):e030912. PubMed ID: 31780589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rates and predictors of relapse following discontinuation of antipsychotic medication after a first episode of psychosis.
    Bowtell M; Eaton S; Thien K; Bardell-Williams M; Downey L; Ratheesh A; Killackey E; McGorry P; O'Donoghue B
    Schizophr Res; 2018 May; 195():231-236. PubMed ID: 29066258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antidepressant medication to prevent depression relapse in primary care: the ANTLER RCT.
    Duffy L; Clarke CS; Lewis G; Marston L; Freemantle N; Gilbody S; Hunter R; Kendrick T; Kessler D; King M; Lanham P; Mangin D; Moore M; Nazareth I; Wiles N; Bacon F; Bird M; Brabyn S; Burns A; Donkor Y; Hunt A; Pervin J; Lewis G
    Health Technol Assess; 2021 Nov; 25(69):1-62. PubMed ID: 34842135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review.
    Zipursky RB; Menezes NM; Streiner DL
    Schizophr Res; 2014 Feb; 152(2-3):408-14. PubMed ID: 23972821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.